SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptional activating p53 in lung cancer

Oncogene

Volumn 34, Issue 33, 2015, Pages 4391-4402

  Han, F ^a,b   Liu, W ^a,b   Jiang, X ^a,b   Shi, X ^a,b   Yin, L ^a,b   Ao, L ^a,b   Cui, Z ^a,b   Li, Y ^a,b   Huang, C ^c   Cao, J ^a,b   Liu, J ^a,b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; PROTEIN P53; TRANSCRIPTION FACTOR SOX; TRANSCRIPTION FACTOR SOX30; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE FREQUENCY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LUNG CANCER; LUNG CANCER CELL LINE; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR GROWTH; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; LUNG TUMOR; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; PROMOTER REGIONS, GENETIC; SOX TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939571899     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.370     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
4. Yang IV, Schwartz DA. Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med 2011; 183: 1295-1301.
5. Minguez B, Lachenmayer A. Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers 2011; 31: 181-190.
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 2003; 349: 2042-2054.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
8. Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC, Lin WC et al. SOX1 functions as a tumor suppressor by antagonizing the WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Hepatology 2012; 56: 2277-2287.
9. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-1099.
10. Khare S, Verma M. Epigenetics of colon cancer. Methods Mol Biol 2012; 863: 177-185.
11. Zitt M, Zitt M, Muller HM. DNA methylation in colorectal cancer-impact on screening and therapy monitoring modalities? Dis Markers 2007; 23: 51-71.
12. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
13. Patai AV, Molnar B, Kalmar A, Scholler A, Toth K, Tulassay Z. Role of DNA methylation in colorectal carcinogenesis. Dig Dis 2012; 30: 310-315.
14. Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Mnsterberg A et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990; 346: 245-250.
15. Chew LJ, Gallo V. The Yin and Yang of Sox proteins: Activation and repression in development and disease. J Neurosci Res 2009; 87: 3277-3287.
16. Osaki E, Nishina Y, Inazawa J, Copeland NG, Gilbert DJ, Jenkins NA et al. Identification of a novel Sry-related gene and its germ cell-specific expression. Nucleic Acids Res 1999; 27: 2503-2510.
17. Han F, Wang Z, Wu F, Liu Z, Huang B, Wang D. Characterization, phylogeny, alternative splicing and expression of Sox30 gene. BMC Mol Biol 2010; 11: 98.
18. Ballow D, Meistrich ML, Matzuk M, Rajkovic A. Sohlh1 is essential for spermatogonial differentiation. Dev Biol 2006; 294: 161-167.
19. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-2097.
20. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
21. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88: 6961-6965.
22. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
23. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.
24. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
25. Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, Tannapfel A et al. The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene 2008; 27: 4557-4568.
26. Seo YW, Shin JN, Ko KH, Cha JH, Park JY, Lee BR et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J Biol Chem 2003; 278: 48292-48299.
27. Suzuki S, Nakasato M, Shibue T, Koshima I, Taniguchi T. Therapeutic potential of proapoptotic molecule Noxa in the selective elimination of tumor cells. Cancer Sci 2009; 100: 759-769.
28. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
29. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
30. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
31. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-557.
32. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001; 77: 220-228.
33. Plesnila N, von Baumgarten L, Retiounskaia M, Engel D, Ardeshiri A, Zimmermann R et al. Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. Cell Death Differ 2007; 14: 1529-1541.
34. Kim HR, Jung MH, Lee SY, Oh SM, Chung KH. Marijuana smoke condensate induces p53-mediated apoptosis in human lung epithelial cells. J Toxicol Sci 2013; 38: 337-347.
35. Gorgoulis VG, Zacharatos P, Kotsinas A, Kletsas D, Mariatos G, Zoumpourlis V et al. p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. EMBO J 2003; 22: 1567-1578.
36. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 2004; 23: 3541-3549.
37. Gudkov AV, Komarova EA. Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 2005; 331: 726-736.
38. Liu WB, Han F, Jiang X, Yang LJ, Li YH, Liu Y et al. ANKRD18A as a novel epigenetic regulation gene in lung cancer. Biochem Biophys Res Commun 2012; 429: 180-185.
39. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593.
40. Liu WB, Liu JY, Ao L, Zhou ZY, Zhou YH, Cui ZH et al. Epigenetic silencing of cell cycle regulatory genes during 3-methylcholanthrene and diethylnitrosamine-induced multistep rat lung cancer. Mol Carcinog 2010; 49: 556-565.
41. Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF et al. Expression of Frzb/ secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 2005; 65: 9762-9770.